Leo Phar­ma of­floads a pso­ri­a­sis as­set as their Dupix­ent ri­val heads to the FDA

Leo Phar­ma, a small, cen­tu­ry-old Dan­ish drug­mak­er, has spent the past few years tail­ing Sanofi on their fran­chise drug Dupix­ent, bet­ting that an an­ti­body they li­censed from As­traZeneca cou­pled with a few decades of ex­per­tise in der­ma­tol­ogy could com­pete with one of Big Phar­ma’s biggest drugs. They got a huge boost in that re­gard in De­cem­ber, with pos­i­tive Phase III re­sults in atopic der­mati­tis, and last week, when they an­nounced the FDA had ac­cept­ed their BLA for the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.